APO Research
Talk to an analyst

APO RESEARCH · REPORT

Overactive Bladder Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Overactive Bladder Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025192 pages

Choose your research edition.

Industry ResearchOveractive Bladder Drug Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Overactive Bladder Drug Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Overactive Bladder Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Overactive Bladder Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Overactive Bladder Drug Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Overactive Bladder Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Overactive Bladder Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Overactive Bladder Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Overactive Bladder Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Overactive Bladder Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Overactive Bladder Drug include Allergan, Plc (Ireland), Apotex, Inc. (Canada), Astellas Pharma, Inc. (Japan), Aurobindo Pharma Limited (India), Cogentix Medical, Inc. (US), Endo International plc (Ireland), Hisamitsu Pharmaceutical Co., Inc. (Japan), Medtronic plc (Ireland) and Pfizer, Inc. (US), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Overactive Bladder Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Overactive Bladder Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Overactive Bladder Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Overactive Bladder Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Overactive Bladder Drug Segment by Company

Allergan, Plc (Ireland)

Apotex, Inc. (Canada)

Astellas Pharma, Inc. (Japan)

Aurobindo Pharma Limited (India)

Cogentix Medical, Inc. (US)

Endo International plc (Ireland)

Hisamitsu Pharmaceutical Co., Inc. (Japan)

Medtronic plc (Ireland)

Pfizer, Inc. (US)

Mylan N.V. (US)

Sanofi (France)

Teva Pharmaceutical Industries Limited (Israel)

Overactive Bladder Drug Segment by Type

Tolterodine

Solifenacin

Trospium

Anticholinergics

Fesoterodine

Darifenacin

Oxybutynin

Others

Overactive Bladder Drug Segment by Application

Idiopathic Bladder Overactivity

Neurogenic Bladder Overactivity

Overactive Bladder Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Overactive Bladder Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Overactive Bladder Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Overactive Bladder Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Overactive Bladder Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Overactive Bladder Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Overactive Bladder Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Overactive Bladder Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Overactive Bladder Drug Industry Trends Table 2. Overactive Bladder Drug Industry Drivers Table 3. Overactive Bladder Drug Industry Opportunities and Challenges Table 4. Overactive Bladder Drug Industry Restraints Table 5. Global Overactive Bladder Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Overactive Bladder Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Overactive Bladder Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Overactive Bladder Drug Sales Market Share by Manufacturers Table 9. Global Overactive Bladder Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Overactive Bladder Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Overactive Bladder Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Overactive Bladder Drug Manufacturers, Product Type & Application Table 13. Global Overactive Bladder Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Overactive Bladder Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Tolterodine Table 17. Major Manufacturers of Solifenacin Table 18. Major Manufacturers of Trospium Table 19. Major Manufacturers of Anticholinergics Table 20. Major Manufacturers of Fesoterodine Table 21. Major Manufacturers of Darifenacin Table 22. Major Manufacturers of Oxybutynin Table 23. Major Manufacturers of Others Table 24. Global Overactive Bladder Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Overactive Bladder Drug Sales by Type (2021-2026) & (K Units) Table 26. Global Overactive Bladder Drug Sales by Type (2027-2032) & (K Units) Table 27. Global Overactive Bladder Drug Sales Market Share by Type (2021-2026) Table 28. Global Overactive Bladder Drug Sales Market Share by Type (2027-2032) Table 29. Global Overactive Bladder Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 30. Global Overactive Bladder Drug Revenue by Type (2021-2026) & (K Units) Table 31. Global Overactive Bladder Drug Revenue by Type (2027-2032) & (K Units) Table 32. Global Overactive Bladder Drug Revenue Market Share by Type (2021-2026) Table 33. Global Overactive Bladder Drug Revenue Market Share by Type (2027-2032) Table 34. Major Manufacturers of Idiopathic Bladder Overactivity Table 35. Major Manufacturers of Neurogenic Bladder Overactivity Table 36. Global Overactive Bladder Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Overactive Bladder Drug Sales by Application (2021-2026) & (K Units) Table 38. Global Overactive Bladder Drug Sales by Application (2027-2032) & (K Units) Table 39. Global Overactive Bladder Drug Sales Market Share by Application (2021-2026) Table 40. Global Overactive Bladder Drug Sales Market Share by Application (2027-2032) Table 41. Global Overactive Bladder Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 42. Global Overactive Bladder Drug Revenue by Application (2021-2026) & (K Units) Table 43. Global Overactive Bladder Drug Revenue by Application (2027-2032) & (K Units) Table 44. Global Overactive Bladder Drug Revenue Market Share by Application (2021-2026) Table 45. Global Overactive Bladder Drug Revenue Market Share by Application (2027-2032) Table 46. Global Overactive Bladder Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Overactive Bladder Drug Sales by Region (2021-2026) & (K Units) Table 48. Global Overactive Bladder Drug Sales Market Share by Region (2021-2026) Table 49. Global Overactive Bladder Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 50. Global Overactive Bladder Drug Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Overactive Bladder Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. North America Overactive Bladder Drug Sales by Country (2021-2026) & (K Units) Table 53. North America Overactive Bladder Drug Sales by Country (2027-2032) & (K Units) Table 54. Europe Overactive Bladder Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Europe Overactive Bladder Drug Sales by Country (2021-2026) & (K Units) Table 56. Europe Overactive Bladder Drug Sales by Country (2027-2032) & (K Units) Table 57. Asia Pacific Overactive Bladder Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Asia Pacific Overactive Bladder Drug Sales by Country (2021-2026) & (K Units) Table 59. Asia Pacific Overactive Bladder Drug Sales by Country (2027-2032) & (K Units) Table 60. South America, Middle East and Africa Overactive Bladder Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. South America, Middle East and Africa Overactive Bladder Drug Sales by Country (2021-2026) & (K Units) Table 62. South America, Middle East and Africa Overactive Bladder Drug Sales by Country (2027-2032) & (K Units) Table 63. Global Overactive Bladder Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Overactive Bladder Drug Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Overactive Bladder Drug Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Overactive Bladder Drug Revenue Market Share by Region (2021-2026) Table 67. Global Overactive Bladder Drug Revenue Market Share by Region (2027-2032) Table 68. Allergan, Plc (Ireland) Company Information Table 69. Allergan, Plc (Ireland) Business Overview Table 70. Allergan, Plc (Ireland) Overactive Bladder Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Allergan, Plc (Ireland) Overactive Bladder Drug Product Portfolio Table 72. Allergan, Plc (Ireland) Recent Development Table 73. Apotex, Inc. (Canada) Company Information Table 74. Apotex, Inc. (Canada) Business Overview Table 75. Apotex, Inc. (Canada) Overactive Bladder Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Apotex, Inc. (Canada) Overactive Bladder Drug Product Portfolio Table 77. Apotex, Inc. (Canada) Recent Development Table 78. Astellas Pharma, Inc. (Japan) Company Information Table 79. Astellas Pharma, Inc. (Japan) Business Overview Table 80. Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Product Portfolio Table 82. Astellas Pharma, Inc. (Japan) Recent Development Table 83. Aurobindo Pharma Limited (India) Company Information Table 84. Aurobindo Pharma Limited (India) Business Overview Table 85. Aurobindo Pharma Limited (India) Overactive Bladder Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Aurobindo Pharma Limited (India) Overactive Bladder Drug Product Portfolio Table 87. Aurobindo Pharma Limited (India) Recent Development Table 88. Cogentix Medical, Inc. (US) Company Information Table 89. Cogentix Medical, Inc. (US) Business Overview Table 90. Cogentix Medical, Inc. (US) Overactive Bladder Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Cogentix Medical, Inc. (US) Overactive Bladder Drug Product Portfolio Table 92. Cogentix Medical, Inc. (US) Recent Development Table 93. Endo International plc (Ireland) Company Information Table 94. Endo International plc (Ireland) Business Overview Table 95. Endo International plc (Ireland) Overactive Bladder Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Endo International plc (Ireland) Overactive Bladder Drug Product Portfolio Table 97. Endo International plc (Ireland) Recent Development Table 98. Hisamitsu Pharmaceutical Co., Inc. (Japan) Company Information Table 99. Hisamitsu Pharmaceutical Co., Inc. (Japan) Business Overview Table 100. Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Product Portfolio Table 102. Hisamitsu Pharmaceutical Co., Inc. (Japan) Recent Development Table 103. Medtronic plc (Ireland) Company Information Table 104. Medtronic plc (Ireland) Business Overview Table 105. Medtronic plc (Ireland) Overactive Bladder Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Medtronic plc (Ireland) Overactive Bladder Drug Product Portfolio Table 107. Medtronic plc (Ireland) Recent Development Table 108. Pfizer, Inc. (US) Company Information Table 109. Pfizer, Inc. (US) Business Overview Table 110. Pfizer, Inc. (US) Overactive Bladder Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Pfizer, Inc. (US) Overactive Bladder Drug Product Portfolio Table 112. Pfizer, Inc. (US) Recent Development Table 113. Mylan N.V. (US) Company Information Table 114. Mylan N.V. (US) Business Overview Table 115. Mylan N.V. (US) Overactive Bladder Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Mylan N.V. (US) Overactive Bladder Drug Product Portfolio Table 117. Mylan N.V. (US) Recent Development Table 118. Sanofi (France) Company Information Table 119. Sanofi (France) Business Overview Table 120. Sanofi (France) Overactive Bladder Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Sanofi (France) Overactive Bladder Drug Product Portfolio Table 122. Sanofi (France) Recent Development Table 123. Teva Pharmaceutical Industries Limited (Israel) Company Information Table 124. Teva Pharmaceutical Industries Limited (Israel) Business Overview Table 125. Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Product Portfolio Table 127. Teva Pharmaceutical Industries Limited (Israel) Recent Development Table 128. Key Raw Materials Table 129. Raw Materials Key Suppliers Table 130. Overactive Bladder Drug Distributors List Table 131. Overactive Bladder Drug Customers List Table 132. Research Programs/Design for This Report Table 133. Authors List of This Report Table 134. Secondary Sources Table 135. Primary Sources List of Figures Figure 1. Overactive Bladder Drug Product Image Figure 2. Global Overactive Bladder Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Overactive Bladder Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Overactive Bladder Drug Sales (2021-2032) & (K Units) Figure 5. Global Overactive Bladder Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Overactive Bladder Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Tolterodine Image Figure 9. Solifenacin Image Figure 10. Trospium Image Figure 11. Anticholinergics Image Figure 12. Fesoterodine Image Figure 13. Darifenacin Image Figure 14. Oxybutynin Image Figure 15. Others Image Figure 16. Global Overactive Bladder Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Overactive Bladder Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 18. Global Overactive Bladder Drug Sales Market Share by Type (2021-2032) Figure 19. Global Overactive Bladder Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Overactive Bladder Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Overactive Bladder Drug Revenue Market Share by Type (2021-2032) Figure 22. Idiopathic Bladder Overactivity Image Figure 23. Neurogenic Bladder Overactivity Image Figure 24. Global Overactive Bladder Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Overactive Bladder Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Overactive Bladder Drug Sales Market Share by Application (2021-2032) Figure 27. Global Overactive Bladder Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 28. Global Overactive Bladder Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Overactive Bladder Drug Revenue Market Share by Application (2021-2032) Figure 30. North America Overactive Bladder Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 31. North America Overactive Bladder Drug Sales Market Share by Country (2021-2032) Figure 32. U.S. Overactive Bladder Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Canada Overactive Bladder Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Mexico Overactive Bladder Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Overactive Bladder Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe Overactive Bladder Drug Sales Market Share by Country (2021-2032) Figure 37. Germany Overactive Bladder Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. France Overactive Bladder Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. U.K. Overactive Bladder Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Italy Overactive Bladder Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Netherlands Overactive Bladder Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Overactive Bladder Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific Overactive Bladder Drug Sales Market Share by Country (2021-2032) Figure 44. China Overactive Bladder Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Japan Overactive Bladder Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South Korea Overactive Bladder Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Southeast Asia Overactive Bladder Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. India Overactive Bladder Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Australia Overactive Bladder Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Overactive Bladder Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa Overactive Bladder Drug Sales Market Share by Country (2021-2032) Figure 52. Brazil Overactive Bladder Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. South Africa Overactive Bladder Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Saudi Arabia Overactive Bladder Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Turkey Overactive Bladder Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Argentina Overactive Bladder Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. UAE Overactive Bladder Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Egypt Overactive Bladder Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Chile Overactive Bladder Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Global Overactive Bladder Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Overactive Bladder Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Overactive Bladder Drug Revenue (2021-2032) & (US$ Million) Figure 63. North America Overactive Bladder Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Overactive Bladder Drug Revenue (2021-2032) & (US$ Million) Figure 65. Europe Overactive Bladder Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Overactive Bladder Drug Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Overactive Bladder Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Overactive Bladder Drug Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Overactive Bladder Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Overactive Bladder Drug Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Overactive Bladder Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Tolterodine
  • Solifenacin
  • Trospium
  • Anticholinergics
  • Fesoterodine
  • Darifenacin
  • Oxybutynin
  • Others
Applications
  • Idiopathic Bladder Overactivity
  • Neurogenic Bladder Overactivity
Companies covered
  • Allergan, Plc (Ireland)
  • Apotex, Inc. (Canada)
  • Astellas Pharma, Inc. (Japan)
  • Aurobindo Pharma Limited (India)
  • Cogentix Medical, Inc. (US)
  • Endo International plc (Ireland)
  • Hisamitsu Pharmaceutical Co., Inc. (Japan)
  • Medtronic plc (Ireland)
  • Pfizer, Inc. (US)
  • Mylan N.V. (US)
  • Sanofi (France)
  • Teva Pharmaceutical Industries Limited (Israel)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Overactive Bladder Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Overactive Bladder Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Overactive Bladder Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Overactive Bladder Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Overactive Bladder Drug Market Dynamics
  1. 2.1 Overactive Bladder Drug Industry Trends
  2. 2.2 Overactive Bladder Drug Industry Drivers
  3. 2.3 Overactive Bladder Drug Industry Opportunities and Challenges
  4. 2.4 Overactive Bladder Drug Industry Restraints
3 Overactive Bladder Drug Market by Manufacturers
  1. 3.1 Global Overactive Bladder Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Overactive Bladder Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Overactive Bladder Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Overactive Bladder Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Overactive Bladder Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Overactive Bladder Drug Manufacturers, Product Type & Application
  7. 3.7 Global Overactive Bladder Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Overactive Bladder Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Overactive Bladder Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Overactive Bladder Drug Tier 1, Tier 2, and Tier 3
4 Overactive Bladder Drug Market by Type
  1. 4.1 Overactive Bladder Drug Type Introduction
  2. 4.1.1 Tolterodine
  3. 4.1.2 Solifenacin
  4. 4.1.3 Trospium
  5. 4.1.4 Anticholinergics
  6. 4.1.5 Fesoterodine
  7. 4.1.6 Darifenacin
  8. 4.1.7 Oxybutynin
  9. 4.1.8 Others
  10. 4.2 Global Overactive Bladder Drug Sales by Type
  11. 4.2.1 Global Overactive Bladder Drug Sales by Type (2021 VS 2025 VS 2032)
  12. 4.2.2 Global Overactive Bladder Drug Sales by Type (2021-2032)
  13. 4.2.3 Global Overactive Bladder Drug Sales Market Share by Type (2021-2032)
  14. 4.3 Global Overactive Bladder Drug Revenue by Type
  15. 4.3.1 Global Overactive Bladder Drug Revenue by Type (2021 VS 2025 VS 2032)
  16. 4.3.2 Global Overactive Bladder Drug Revenue by Type (2021-2032)
  17. 4.3.3 Global Overactive Bladder Drug Revenue Market Share by Type (2021-2032)
5 Overactive Bladder Drug Market by Application
  1. 5.1 Overactive Bladder Drug Application Introduction
  2. 5.1.1 Idiopathic Bladder Overactivity
  3. 5.1.2 Neurogenic Bladder Overactivity
  4. 5.2 Global Overactive Bladder Drug Sales by Application
  5. 5.2.1 Global Overactive Bladder Drug Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Overactive Bladder Drug Sales by Application (2021-2032)
  7. 5.2.3 Global Overactive Bladder Drug Sales Market Share by Application (2021-2032)
  8. 5.3 Global Overactive Bladder Drug Revenue by Application
  9. 5.3.1 Global Overactive Bladder Drug Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Overactive Bladder Drug Revenue by Application (2021-2032)
  11. 5.3.3 Global Overactive Bladder Drug Revenue Market Share by Application (2021-2032)
6 Global Overactive Bladder Drug Sales by Region
  1. 6.1 Global Overactive Bladder Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Overactive Bladder Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Overactive Bladder Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Overactive Bladder Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Overactive Bladder Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Overactive Bladder Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Overactive Bladder Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Overactive Bladder Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Overactive Bladder Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Overactive Bladder Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Overactive Bladder Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Overactive Bladder Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Overactive Bladder Drug Revenue by Region
  1. 7.1 Global Overactive Bladder Drug Revenue by Region
  2. 7.1.1 Global Overactive Bladder Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Overactive Bladder Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Overactive Bladder Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Overactive Bladder Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Overactive Bladder Drug Revenue (2021-2032)
  8. 7.2.2 North America Overactive Bladder Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Overactive Bladder Drug Revenue (2021-2032)
  11. 7.3.2 Europe Overactive Bladder Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Overactive Bladder Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Overactive Bladder Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Overactive Bladder Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Overactive Bladder Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Allergan, Plc (Ireland)
  2. 8.1.1 Allergan, Plc (Ireland) Company Information
  3. 8.1.2 Allergan, Plc (Ireland) Business Overview
  4. 8.1.3 Allergan, Plc (Ireland) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Allergan, Plc (Ireland) Overactive Bladder Drug Product Portfolio
  6. 8.1.5 Allergan, Plc (Ireland) Recent Developments
  7. 8.2 Apotex, Inc. (Canada)
  8. 8.2.1 Apotex, Inc. (Canada) Company Information
  9. 8.2.2 Apotex, Inc. (Canada) Business Overview
  10. 8.2.3 Apotex, Inc. (Canada) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Apotex, Inc. (Canada) Overactive Bladder Drug Product Portfolio
  12. 8.2.5 Apotex, Inc. (Canada) Recent Developments
  13. 8.3 Astellas Pharma, Inc. (Japan)
  14. 8.3.1 Astellas Pharma, Inc. (Japan) Company Information
  15. 8.3.2 Astellas Pharma, Inc. (Japan) Business Overview
  16. 8.3.3 Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Product Portfolio
  18. 8.3.5 Astellas Pharma, Inc. (Japan) Recent Developments
  19. 8.4 Aurobindo Pharma Limited (India)
  20. 8.4.1 Aurobindo Pharma Limited (India) Company Information
  21. 8.4.2 Aurobindo Pharma Limited (India) Business Overview
  22. 8.4.3 Aurobindo Pharma Limited (India) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Aurobindo Pharma Limited (India) Overactive Bladder Drug Product Portfolio
  24. 8.4.5 Aurobindo Pharma Limited (India) Recent Developments
  25. 8.5 Cogentix Medical, Inc. (US)
  26. 8.5.1 Cogentix Medical, Inc. (US) Company Information
  27. 8.5.2 Cogentix Medical, Inc. (US) Business Overview
  28. 8.5.3 Cogentix Medical, Inc. (US) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Cogentix Medical, Inc. (US) Overactive Bladder Drug Product Portfolio
  30. 8.5.5 Cogentix Medical, Inc. (US) Recent Developments
  31. 8.6 Endo International plc (Ireland)
  32. 8.6.1 Endo International plc (Ireland) Company Information
  33. 8.6.2 Endo International plc (Ireland) Business Overview
  34. 8.6.3 Endo International plc (Ireland) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Endo International plc (Ireland) Overactive Bladder Drug Product Portfolio
  36. 8.6.5 Endo International plc (Ireland) Recent Developments
  37. 8.7 Hisamitsu Pharmaceutical Co., Inc. (Japan)
  38. 8.7.1 Hisamitsu Pharmaceutical Co., Inc. (Japan) Company Information
  39. 8.7.2 Hisamitsu Pharmaceutical Co., Inc. (Japan) Business Overview
  40. 8.7.3 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Product Portfolio
  42. 8.7.5 Hisamitsu Pharmaceutical Co., Inc. (Japan) Recent Developments
  43. 8.8 Medtronic plc (Ireland)
  44. 8.8.1 Medtronic plc (Ireland) Company Information
  45. 8.8.2 Medtronic plc (Ireland) Business Overview
  46. 8.8.3 Medtronic plc (Ireland) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Medtronic plc (Ireland) Overactive Bladder Drug Product Portfolio
  48. 8.8.5 Medtronic plc (Ireland) Recent Developments
  49. 8.9 Pfizer, Inc. (US)
  50. 8.9.1 Pfizer, Inc. (US) Company Information
  51. 8.9.2 Pfizer, Inc. (US) Business Overview
  52. 8.9.3 Pfizer, Inc. (US) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer, Inc. (US) Overactive Bladder Drug Product Portfolio
  54. 8.9.5 Pfizer, Inc. (US) Recent Developments
  55. 8.10 Mylan N.V. (US)
  56. 8.10.1 Mylan N.V. (US) Company Information
  57. 8.10.2 Mylan N.V. (US) Business Overview
  58. 8.10.3 Mylan N.V. (US) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Mylan N.V. (US) Overactive Bladder Drug Product Portfolio
  60. 8.10.5 Mylan N.V. (US) Recent Developments
  61. 8.11 Sanofi (France)
  62. 8.11.1 Sanofi (France) Company Information
  63. 8.11.2 Sanofi (France) Business Overview
  64. 8.11.3 Sanofi (France) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sanofi (France) Overactive Bladder Drug Product Portfolio
  66. 8.11.5 Sanofi (France) Recent Developments
  67. 8.12 Teva Pharmaceutical Industries Limited (Israel)
  68. 8.12.1 Teva Pharmaceutical Industries Limited (Israel) Company Information
  69. 8.12.2 Teva Pharmaceutical Industries Limited (Israel) Business Overview
  70. 8.12.3 Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Product Portfolio
  72. 8.12.5 Teva Pharmaceutical Industries Limited (Israel) Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Overactive Bladder Drug Value Chain Analysis
  2. 9.1.1 Overactive Bladder Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Overactive Bladder Drug Production Mode & Process
  6. 9.2 Overactive Bladder Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Overactive Bladder Drug Distributors
  9. 9.2.3 Overactive Bladder Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst